The technology is available on the new MyLab™E85 GTS Edition, which will be showcased alongside the brand-new MyLab™C30 GTS ultrasound system at the Esaote booth. LONDON, March 13, 2026 /PRNewswire/ — Esaote Group, a leading Italian innovator in the field of medical imaging (ultrasound, dedicated MRI, and medical IT), reinforces its position as a top provider of advanced imaging and guided therapy solutions for urologists at the 41st Annual Congress of the European Association of Urology (EAU), currently taking place in London (March 13-16, 2026).
Esaote presents its new groundbreaking urology-specific technology: the exclusive Prostate Attention Map (PAM) solution is now available on the new MyLab™E85 GTS. Esaote will also introduce the new MyLab™C30 GTS, offering high-quality imaging performance on a portable system to cater to various examination scenarios.
Throughout the congress, Esaote (booth N16) showcases a comprehensive range designed to enhance diagnostic accuracy and intervention guidance in prostate care, emphasizing trust, efficiency, and clinical excellence. The PAM technology lies at the heart of this innovation, providing automatic analysis of multiparametric MRI prostate volumes and identifying suspicious target regions, assisting urologists in improving target orientation and decision-making.
“The PAM technology is fully integrated into Esaote’s UroFusion software,” stated Marta Daniel, Product Manager for Guided Therapy and Clinical Solutions at Esaote. “Our UroFusion suite is designed to provide focal guidance during targeted prostate biopsies. With AI, urologists have an optimal workflow, similar duration to standard biopsy procedures, while enhancing confidence and precision during biopsy procedures.”
During the congress, Esaote actively participates in practical sessions TP Biopsy and MRI-US Fusion, led by internationally recognized specialists, offering participants the chance to explore the latest advancements in UroFusion.
Esaote’s involvement at EAU 2026, featuring the presentation of PAM technology and the launch of two urology-specific systems, represents a significant expansion of Esaote’s Guided Therapy Solutions (GTS) range and underscores the company’s ongoing commitment to provide urologists with reliable, intelligent, and clinically relevant imaging solutions that offer advanced image quality, intuitive interaction, and seamless fusion workflows in prostate treatment.
Esaote Group is a leader in medical imaging (ultrasound, MRI, and diagnostic process management software). By the end of 2025, the group had 1,300 employees, half of whom were in Italy. With facilities in Genoa and Florence and its manufacturing and research units in Italy and the Netherlands, Esaote operates in over 100 countries worldwide. www.esaote.com
Photo – https://mma.prnewswire.com/media/2932913/Esaote_PAM.jpg Logo – https://mma.prnewswire.com/media/2931806/ESAOTE_Logo.jpg
